Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm FCN-159 in extracranial arteriovenous malformation
ChiCTR2500096055Phase 2Not yet recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of luvometinib in extracranial arteriovenous malformation (EAVM), sponsored by Shanghai Ninth People's Hospital. Primary endpoint: Objective response rate. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
luvometinib
03
Conditions
extracranial arteriovenous malformation (EAVM)
Beyond the preview
Go deeper on ChiCTR2500096055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500096055.